Sirtuin Activator Complex.

Resveratrol is the stilbene that defined this class, acting on SIRT1 allosterically with certain substrates and through AMPK upstream. It is the reference compound any activator stack is built around.

Pterostilbene is the dimethylated form of resveratrol, which resists phase II conjugation and reaches far higher plasma exposure for the same dose. It targets the same stilbene pathway with better systemic availability.

Every sirtuin is an NAD-dependent deacylase that consumes one NAD molecule per reaction, so the cofactor pool sets the ceiling on activity. NMN is the immediate precursor NAMPT product that feeds that pool through NMNAT.

NR is phosphorylated by NRK1 and NRK2 to NMN and then to NAD, entering the same salvage pathway one step earlier. It raises the cofactor the stilbene activators need in order to have anything to act on.

Nicotinamide is the by-product released when a sirtuin cleaves NAD, and it binds the enzyme's C-pocket to drive the reaction backwards, making it a direct non-competitive inhibitor of sirtuin deacetylation. High free nicotinamide therefore works against the very enzymes an activator stack targets, which is why NMN and NR are preferred as precursors.

Excess nicotinamide is cleared by nicotinamide N-methyltransferase, which consumes a methyl group from S-adenosylmethionine for each molecule. Betaine restores that methyl pool through the BHMT route, which is why it is routinely paired with NAD precursors.

Nicotinic acid enters NAD synthesis through the Preiss-Handler route, a separate entry point from the nicotinamide salvage pathway. It raises the same cofactor pool without contributing free nicotinamide directly.

Apigenin inhibits CD38, the main NAD-consuming glycohydrolase in tissue, which slows the drain on the pool rather than adding to it. Pairing an inhibitor of consumption with a precursor works on both sides of the same balance.

Quercetin and resveratrol compete for the same sulfotransferase and UGT isoforms in the gut wall and liver, so co-dosing raises the unconjugated stilbene reaching circulation. Quercetin is also a CD38 inhibitor in its own right.

Piperine inhibits intestinal and hepatic glucuronidation, the main clearance route for resveratrol and pterostilbene. It is the standard bioavailability partner for heavily conjugated polyphenols.

Spermidine inhibits EP300 acetyltransferase, producing protein hypoacetylation and autophagy induction, which is the same directional outcome sirtuin deacetylases produce from the opposite enzymatic side. The two converge on the acetylation state of autophagy proteins.

Urolithin A, produced by gut bacteria from ellagitannins, induces mitophagy and the turnover of damaged mitochondria. That sits downstream of the same PGC-1alpha and mitochondrial biogenesis axis SIRT1 deacetylation feeds into.

Berberine raises the AMP to ATP ratio and activates AMPK, which in turn raises NAD availability and SIRT1 activity in a reciprocal loop. It approaches the same node from the energy-sensing side.

PQQ is associated with PGC-1alpha signalling and new mitochondrial formation, the same effector SIRT1 acts on when it deacetylates PGC-1alpha. The two reach one downstream target by different routes.

NAD is the obligate co-substrate consumed by every sirtuin reaction, so its availability is the rate limit on the enzyme family the stack targets. Oral NAD is largely broken down to its precursors before uptake, which is the practical reason NMN and NR are used instead.

A systematic review of rodent studies on omega-3 fatty acids and diet-induced excess body weight discusses sirtuin signalling among the mechanisms reported. That is animal evidence for a shared pathway, not human evidence for a combination effect. EPA and DHA also act through PPAR signalling that sirtuins interact with, which is the mechanistic reason the two are combined.

NADH delivers electrons to complex I, and coenzyme Q10 carries them onward to complex III. Raising NAD+ availability without a functioning quinone pool moves the bottleneck rather than removing it. The electron transport sequence is textbook, and the pairing addresses two consecutive steps of it.

Lipoamide is covalently bound in the E2 subunit of the pyruvate dehydrogenase complex, which consumes NAD+ as its electron acceptor. That places lipoic acid directly on the NAD-cycling side of metabolism where sirtuins draw their substrate. The cofactor relationship is settled biochemistry and needs no citation.

Riboflavin becomes FAD and FMN, which serve complex I, complex II and the E3 subunit shared by the pyruvate and alpha-ketoglutarate dehydrogenase complexes. Those enzymes are where NADH is produced and reoxidised. Feeding NAD precursors while flavin cofactors are short leaves the recycling side undersupplied.

Nicotinamide riboside kinase and the adenylyltransferase steps of NAD synthesis run on Mg-ATP, because ATP is functionally always a magnesium complex in the cell. Every phosphorylation step in the salvage pathway therefore depends on magnesium status. This is textbook enzymology rather than a supplement claim.

Carnitine palmitoyltransferase governs entry of long-chain fatty acids into the mitochondrion, and beta-oxidation is a major NADH-producing route. SIRT3 is described as a mitochondrial deacetylase acting on enzymes in that same pathway. The link is mechanistic and preclinical, not a demonstrated combination effect in people.

EGCG and the stilbene polyphenols in these stacks share UGT and SULT conjugation capacity, so stacking them changes the exposure of each. High-dose concentrated green tea extract has its own upper intake consideration that is separate from any sirtuin question. Count the total polyphenol load rather than the number of named ingredients.

Curcumin appears in the same preclinical signalling literature as the stilbenes and flavones used in these stacks, and it shares their poor absorption and heavy intestinal conjugation. Co-formulation is common. What is established is the overlap in handling, not an additive effect in people.

Apigenin is included in NAD-focused formulations because flavones of that class inhibit CD38, a major NAD-consuming enzyme, in laboratory systems. Luteolin sits in the same flavone family and behaves similarly in vitro. This is cell and enzyme data, not a measured change in human NAD concentrations.

Mitochondrial membrane composition depends on the phospholipid pool that choline feeds, and the enzymes in these pathways are membrane bound. The link is indirect and preclinical. It is a plausible formulation companion rather than a documented interaction.

Phosphocreatine buffers ATP concentration during rapid demand, while the NAD pool governs the dehydrogenase flux that regenerates that ATP. The two act at different points of the same energy system. Neither has been shown to change the other's behaviour in people, so this is complementary positioning rather than a measured synergy.

NAD can be built de novo from tryptophan via the kynurenine route, which is why the niacin requirement is stated with a tryptophan equivalence. That pathway runs in parallel to the salvage route these stacks target. The precursor relationship is textbook nutritional biochemistry.

Tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase both carry heme, so iron status sits upstream of de novo NAD synthesis. Kynureninase further along the same route is pyridoxal-dependent. These are settled cofactor requirements, not a reason to add iron without a measured need.

The kynurenine pathway stalls at kynureninase without pyridoxal-5-phosphate, which diverts tryptophan away from NAD synthesis. That dependency is classic B6 biochemistry and is why B6 status affects tryptophan-derived niacin equivalence. It runs alongside the salvage pathway rather than through it.

Ascorbate is regenerated from its oxidised forms by NADH- and NADPH-dependent reductases, which ties the vitamin C pool to pyridine nucleotide availability. The recycling chemistry is well described. It is a shared-pool relationship rather than a demonstrated combination benefit.

Reduced glutathione is restored by glutathione reductase at the cost of NADPH, which comes from the same nicotinamide nucleotide family these stacks target. The coupling is textbook redox biochemistry. Note that oral glutathione is largely hydrolysed before absorption, so the delivery question is separate from the biochemistry.